The API Innovation Center, Apertus Pharmaceuticals Bring API Production of Critical Generic Cancer Drug to U.S. Soil
“Apertus Pharmaceuticals is proud to be selected as the contract manufacturer for lomustine,” said David Gindelberger, president and chief scientific officer of Apertus Pharmaceuticals.
- “Apertus Pharmaceuticals is proud to be selected as the contract manufacturer for lomustine,” said David Gindelberger, president and chief scientific officer of Apertus Pharmaceuticals.
- "The St. Louis region is at the forefront of emerging technologies and API production,” said Sen. Brian Williams, D- St. Louis.
- In 2023, the API Innovation Center was awarded $9.5 million from the Missouri Technology Corporation’s Advanced Manufacturing Resiliency Grant Program.
- With this support, the API Innovation Center is investing in building a regional hub for drug advanced manufacturing, establishing Missouri as a leader in domestic API production to secure the U.S. essential drug supply chain.